The Center for Biosimilars® recaps the top stories for the week of January 13, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 13, 2020.
Number 5: A recent study is the latest to find that Samsung Bioepis’ biosimilar SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.
Number 4: The Institute for Clinical and Economic Review released its final report on policy recommendations on the clinical effectiveness and economic value of Janus kinase (JAK) inhibitors for treating rheumatoid arthritis.
Number 3: Two studies recently reported on Hulio, the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics, saying it is equivalent to AbbVie’s reference adalimumab, sold as Humira.
Number 2: In the United States, recent analyses show that biosimilars achieved just 9%, or $91 million, of the $1 billion in cost savings that the Congressional Budget Office projected 10 years ago.
Number 1: An article in JAMA raises concerns that special and accelerated drug approval programs at the FDA may have resulted in a process that approves drugs based on weaker data, without reducing overall drug development time.
To read all of these articles and more, visit centerforbiosimilars.com.
Survey of Clinicians: Lower Cost of Biosimilars is the Main Driver of Treatment Choice in IBD
September 7th 2024Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.